PBYI logo

PBYI
Puma Biotechnology Inc

6,856
Mkt Cap
$395.82M
Volume
317,598.00
52W High
$7.90
52W Low
$2.75
PE Ratio
12.74
PBYI Fundamentals
Price
$7.78
Prev Close
$7.80
Open
$7.81
50D MA
$6.60
Beta
0.92
Avg. Volume
344,579.23
EPS (Annual)
$0.6142
P/B
3.01
Rev/Employee
$1.28M
$230.31
Loading...
Loading...
News
all
press releases
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management
Ritholtz Wealth Management raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 47.4% during the fourth quarter, according to its most recent filing with the...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·4d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving Average - What's Next?
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - What's Next...
MarketBeat·4d ago
News Placeholder
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement...
Business Wire·10d ago
News Placeholder
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·11d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·12d ago
News Placeholder
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy
Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Saturday...
MarketBeat·22d ago
News Placeholder
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Zacks·25d ago
News Placeholder
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Zacks·1mo ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen
Wall Street Zen upgraded Puma Biotechnology from a "hold" rating to a "buy" rating in a report on Sunday...
MarketBeat·1mo ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.